From: The landscape of bispecific T cell engager in cancer treatment
NCT | Phase | Indications | Number of patients | Drug | Target | Results | Reference |
---|---|---|---|---|---|---|---|
NCT01723475 | 1 | Metastatic castration-resistant prostate cancer | 47 | Pasotuxizumab | CD3/PSMA | In SC group (n = 31), > 50% PSA decline rate:21% In cIV group (n = 16), > 50% PSA decline rate:19% | [77] |
NCT03792841 | 1 | Metastatic castration-resistant prostate cancer | 43 | AMG 160 | CD3/PSMA | Any PSA decline rate: 68.6% > 50% PSA decline rate:34.3% In patients with evaluable disease (n = 15), there are 3 PRs and 8 SD | [78] |
NCT03296696 | 1 | R/R Glioblastoma | 15 | AMG 596 | CD3/EGFRvIII | In patients with sufficient follow-up (n = 8), there are 1 PR and 2 SD | [80] |
NCT03319940 | 1 | R/R Small-cell lung cancer | 40 | AMG 757 | CD3/DLL3 | In patients with evaluable disease (n = 38), there are 6 confirmed PRs, 11 SD, and 1 unconfirmed PR | [81] |
NCT04117958 | 1 | Gastric cancer | – | AMG 199 | CD3/MUC 17 | Not reported | [82] |
NCT04260191 | 1` | Gastric cancer | – | AMG 910 | CD3/CLDN18.2 | Not reported | [83] |
NCT04128423 | 1 | R/R solid tumors | 11 | AMV564 | CD3/CD33 | In patients with evaluable disease (n = 9), there are 1 PR and 4 SD | [84] |
NCT02324257 | 1 | CEA+ advanced solid tumors | 80 | Cibisatamab | CD3/CEA | In patients with mCRC at doses ≥60 mg (n = 36) Metabolic PR rate: 28% | [85] |
NCT04501770 | 1 | HER2+ advanced solid tumors | – | M802 | CD3/HER2 | Not reported | [86] |
NCT04501744 | 1 | Malignant ascites | – | M701 | CD3/EpCAM | Not reported | [87] |
NCT02748837 | 1 | Solid malignancies | – | ERY974 | CD3/GPC3 | Not reported | [88] |
NCT02248805 | 1 | R/R Metastatic colorectal carcinoma | 95 | MGD007 | CD3/gpA33 | Not reported | [89] |
NCT02262910 | 1 | Metastatic castration-resistant prostate cancer | 35 | ES414 | CD3/PSMA | Not reported | [90] |
NCT03860207 | 1 | R/R Neuroblastoma, osteosarcoma, and other GD2+ solid tumors | – | Hu3F8-bsAb | CD3/GD2 | Not reported | [91] |
NCT03983395 | 1/2 | HER2+ metastatic breast cancers | – | ISB 1302 | CD3/HER2 | Not reported | – |
NCT03448042 | 1 | Locally advanced or metastatic HER2+ cancers | – | BTRC4017A | CD3/HER2 | Not reported | – |
NCT04424641 | – | Locally advanced or metastatic solid tumors | – | GEN1044 | CD3/5 T4 | Not reported | – |